Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference

SAN DIEGO, Feb. 26, 2015 /PRNewswire/ -- Epic Sciences announced today that President and CEO Murali Prahalad, Ph.D. will present at the 35th Annual Cowen and Company Health Care Conference on Wednesday, March 4, 2015 at 10:00 a.m. EST in the MIT Room, 3rd Floor. The conference will be held at the Boston Marriott Copley Place Hotel in Boston, Mass.

Epic is developing diagnostic tests of high clinical utility to deliver real-time detection of genomic and proteomic changes that occur during the course of cancer treatments. From a simple blood test, Epic's no cell left behind™ technology applies a global, unbiased approach to analyze all possible types of circulating tumor cells to match patients to singular or combination therapies or monitor and understand drug resistance.

About Epic Sciences

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic's mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic's no cell left behind™ technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, Epic has more than 30 collaborations with pharmaceutical companies and leading cancer research centers spanning 67 clinical studies. Epic's goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.

Further information is available on the Company's website, www.epicsciences.com. Stay in touch on Twitter @EpicSciences or Facebook.com/EpicSciences.

SOURCE Epic Sciences

Related Links

http://www.epicsciences.com